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Loss-of-function mutations in the SCN9A gene encoding voltage-gated sodium channel Nav1.7
cause congenital insensitivity to pain in humans and mice. Surprisingly, many potent selective
antagonists of Nav1.7 are weak analgesics. We investigated whether Nav1.7, as well as
contributing to electrical signalling, may have additional functions. Here we report that Nav1.7
deletion has profound effects on gene expression, leading to an upregulation of enkephalin
precursor PenkmRNA and met-enkephalin protein in sensory neurons. In contrast, Nav1.8-null
mutant sensory neurons show no upregulated Penk mRNA expression. Application of the
opioid antagonist naloxone potentiates noxious peripheral input into the spinal cord and
dramatically reduces analgesia in both female and male Nav1.7-null mutant mice, as well as in
a human Nav1.7-null mutant. These data suggest that Nav1.7 channel blockers alone may not
replicate the analgesic phenotype of null mutant humans and mice, but may be potentiated
with exogenous opioids.
DOI: 10.1038/ncomms9967 OPEN
1Molecular Nociception Group, WIBR, University College London, Gower Street, London WC1E 6BT, UK. 2 Department of Neuroscience, Physiology and
Pharmacology, University College London, Gower Street, London WC1E 6BT, UK. 3 Institute of Structural and Molecular Biology, UCL, London WC1E 6BT, UK.
4Department of Medicine, UCL, London WC1E 6BT, UK. * These authors contributed equally to this work. Correspondence and requests for materials should
be addressed to J.N.W. (email: J.Wood@UCL.ac.uk).
NATURE COMMUNICATIONS | 6:8967 | DOI: 10.1038/ncomms9967 | www.nature.com/naturecommunications 1
T
he problem of pain continues to grow as populations age;
about one in ﬁve are victims, with 7% suffering debilitating,
poorly treated chronic pain1. Despite this vast clinical
problem, little progress has been made in developing new
therapeutic agents. Sensory neurons that respond to tissue
damage and drive central pain pathways have been a focus of
analgesic drug development, because nerve block relieves most
pains, and a unique repertoire of sodium channels are found in
peripheral sensory neurons2,3. SCN9A encodes a voltage-gated
sodium channel, Nav1.7, which is found in the peripheral sensory
and sympathetic neurons, as well as in olfactory neurons,
the hypothalamus and some non-neural tissue such as the
pancreas2–5. Deletion of Nav1.7 in sensory and sympathetic
neurons of mice leads to a pain-free congenital insensitivity to
pain (CIP) phenotype similar to that described in humans5–8.
Apart from anosmia, human and mouse Nav1.7-null mutants are
apparently normal, suggesting that this channel is an excellent
analgesic drug target for acute, inﬂammatory and neuropathic
pain. One caveat to this conclusion is that loss of Nav1.7 has also
been associated with peripheral neuropathy in humans and this
could potentially contribute to peripheral analgesia3,9. However,
in Nav1.7-null mutant mouse models that recapitulate the human
CIP phenotype, there is no evidence for any sensory neuronal
cell loss10. Loss of Nav1.7 does result in some mouse sensory
neurons becoming electrically silenced at normal resting
potentials, consistent with a role for Nav1.7 in action potential
propagation in nociceptive neurons11. Nerve block through the
use of broad-spectrum sodium channel antagonists as local
anaesthetics is a very effective way to treat pain, but inhibition of
innocuous sensation makes this approach impractical for most
indications. However, Nav1.7 antagonists are not local
anaesthetics and, if selective, should show none of the side
effects such as cardiotoxicity that are associated with broad-
spectrum sodium channel blockers. Despite considerable efforts,
no evidence for the dramatic analgesia found in Nav1.7-null
mutants has been obtained for compounds such as Protoxin II,
which selectively and potently target Nav1.7, whilst neutralizing
monoclonal antibodies evoke only partial analgesia that lasts for
o24 h (refs 12,13). Here we describe experiments that help
explain this apparent anomaly. We report that Nav1.7 deletion
leads to increased transcription of Penk messenger RNA and
higher levels of enkephalins in sensory neurons. The analgesia
associated with loss of Nav1.7 in both mice and humans is
substantially reversed by the opioid antagonist naloxone.
Thus, Nav1.7 deletion increases endogenous opioid-dependent
analgesia as well as diminishing peripheral nociceptive drive in
pain states.
Results
Many proteins have several, quite distinct functions. For example,
some chromatin proteins such as high-mobility group box 1
protein are also extracellular signalling molecules14, whereas the
b4-subunit of voltage-gated calcium channels has been shown to
have a role as a transcription factor15. We wondered whether
Nav1.7 had an additional role to that of propagating action
potentials. We therefore analysed the patterns of gene expression
in the sensory neurons of dorsal root ganglia (DRG) from Nav1.7,
Nav1.8 and Nav1.9 knockout (KO) mice16–18. Whole dorsal root
ganglia were included in the analysis, but as the sodium channels
are neuronal proteins, alterations in gene expression can be
ascribed to changes in the sensory neuron transcriptome. The
three channels are all expressed at high levels in peripheral
damage-sensing neurons and have been linked to human loss- or
gain-of-function pain conditions2,3. Nav1.9 seems to play a role in
setting thresholds of activation, whereas Nav1.7, which is
expressed in most DRG neurons, transmits action potentials
that are generated by noxious stimuli that depolarize the
neurons18. Nav1.8, which is speciﬁcally expressed in the same
subset of sensory neurons that express Nav1.9, is responsible for
much of the nociceptive electrical input into the central nervous
system and is activated at more negative potentials than Nav1.7.
Nav1.8 seems to be particularly important for nociceptive
signalling at low temperatures2,17. Interestingly, Nav1.7 plays an
essential role in neurotransmitter release, whereas Nav1.8 does
not2,5. Thus, some functions of these sodium channels, both
associated with action potential propagation, are distinct, and this
may reﬂect different biophysical properties, subcellular locations
or association with different protein complexes.
Despite the signiﬁcant role of all three sensory neuron-
associated sodium channels in peripheral pain pathways, we
found a much more dramatic alteration in gene expression in
DRG from mice in which Nav1.7 has been conditionally deleted
from all sensory neurons using Advillin-Cre7 (194 genes41.5 fold
dysregulated; Fig. 1a) than in global Nav1.8 (17 genes)-
or Nav1.9 (64 genes)-null mutant mice (Gene Expression
Omnibus accession number GSE61373). In Nav1.7 conditional
KO mice, a number of transcription factors associated with
sensory neuron subsets were dysregulated including Brn3B, Runx1
and HoxB5 (Fig. 1b). Most strikingly, the levels of Penk mRNA,
the precursor of Leu- and Met-enkephalin19, were upregulated in
Nav1.7, but not in Nav1.8- or Nav1.9-null mutant mice (Fig. 1b
and Supplementary Tables 1 and 2), whereas the transcript of the
little characterized gene Ceacam10 (ref. 20) was dramatically
downregulated in both Nav1.7- and Nav1.8-null mice (Fig. 1b and
Supplementary Table 1). This raised the possibility that
enkephalin-mediated analgesia could contribute to the CIP
phenotype of Nav1.7-null mutant mice and humans.
We conﬁrmed the microarray data on Penk expression using
quantitative PCR (qPCR). We found that Penk mRNA was
upregulated in both female and male Nav1.7-null mutant mice
(Fig. 2a) but not in Nav1.8-null mutant DRG (Fig. 2b), whereas
Ceacam10 mRNA was downregulated in both null mutant mouse
lines (Fig. 2c,d). The overexpression of Penk mRNA was
replicated at the protein level in the central terminals of primary
afferents. Met-enkephalin immunoreactivity was strongly
enhanced in Nav1.7-null mutants compared with littermate
control mice (Fig. 2e). The increase in immunoreactive
Met-enkephalin was more than twofold (Fig. 2f).
How does the loss of a voltage-gated sodium channel alter
levels of transcriptional activity? The activity of Nav1.7 as a major
sodium selective ion channel in sensory neurons could be linked
to altered gene expression through effects on second messengers.
Changes in sodium levels could have an indirect effect
through altered intracellular calcium levels driven by pumps or
the sodium/calcium exchangers found in sensory neurons21.
However, evidence of a direct role for sodium as a transcriptional
regulator has come from studies of atrial myocytes and kidney
medullary cells where intracellular sodium acting through a salt-
dependent kinase can inﬂuence gene expression through
regulation of the transcription factor nuclear factor of activated
T-cells 5 (NFAT5; refs 22,23). A doubling of intracellular sodium
levels in response to carbachol has been described in early studies
of sympathetic neurons24. We examined the consequences of
altering intracellular sodium and calcium levels on Penk and
Ceacam10 mRNA expression. We tested the effects of monensin,
a sodium ionophore that can elevate intracellular sodium levels,
and found that monensin (0.5 mM) could downregulate the
expression of Penk mRNA with no effects on the housekeeping
gene Gapdh in DRG neurons derived from wild-type mice
(Fig. 3a), whereas Ceacam10 expression was enhanced a few-fold
by monensin treatment (Fig. 3b). This suggests a potential role for
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sodium as a second messenger in sensory neurons in terms of
regulation of gene expression.
Calcium is the cation more usually linked to second messenger
activity through interaction with a range of enzymes. Altered
levels of intracellular sodium ions may result in changes in
intracellular calcium through effects on pumps and exchangers21.
Moreover, at high concentrations, monensin is able to increase
intracellular calcium levels in some cells25. We used the calcium
ionophore ionomycin to explore the potential link between
altered calcium levels and gene expression. Ionomycin (0.2 mM),
unlike monensin, had no effect on Penk mRNA levels measured
using qPCR in DRG neurons (Fig. 3c). Interestingly, the increase
in intracellular calcium caused by ionomycin led, as with
monensin treatment, to enhanced expression of Ceacam10
mRNA, showing that calcium-mediated second messenger
regulatory events are at play in sensory neurons in these
experiments (Fig. 3d). However, as the increase in levels of
intracellular calcium had no effect on Penk mRNA levels, sodium
rather than calcium seems to be a key second messenger in
the regulation of opioid peptide expression. To explore the
mechanism of Penk mRNA regulation further, we used the
sodium channel-speciﬁc pore blocker tetrodotoxin (TTX) to
explore changes in gene expression26. The half-maximal
inhibitory concentration (IC50) for TTX is 30 nM for Nav1.7;
however, Nav1.8 is deﬁned as TTX insensitive with an IC50 of
60 mM (refs 16,17). By using TTX at concentrations up to 500 nM,
we could completely block the activity of Nav1.7 and other TTX-
sensitive sodium channels all known to be present in DRG,
whereas Nav1.8 would retain activity. Interestingly, channel block
with TTX leads to an enhanced expression of Penk, slightly lower
in magnitude to that caused by the deletion of Nav1.7 (Fig. 3e),
but is without effect on Ceacam10 expression (Fig. 3f). This
supports the notion that sodium ingress through Nav1.7 channels
downregulates Penk mRNA, although the regulation of Ceacam10
expression requires further investigation.
The present data demonstrate that enkephalins are upregulated
in Nav1.7-null mutant mice. We therefore used the opioid
antagonist naloxone to examine the role of endogenous opioids in
pain behaviour in Nav1.7-null mutant mice27. These mice were
generated by means of an Advillin-Cre mouse that only expresses
recombinase activity in sensory neurons7. Recent RNA
sequencing data highlights the signiﬁcance of the m-opioid
receptor in nociceptive Nav1.8-expressing neurons that do not
contain mRNA for k- or d-opioid receptors28. The target of
naloxone on sensory neurons is thus likely to be the m-opioid
receptor. We used measures of both thermal and mechanical
pain29. When naloxone was administered to ﬂoxed Nav1.7–
Advillin-Cre-null mutant mice, there was a dramatic reversal of
analgesia and restoration of thermal and mechanical pain
thresholds in the Hargreaves and Randall-Selitto tests
respectively, to levels close to that found in littermate controls
(Fig. 4a,b). The dose of naloxone used had no effect on pain
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Figure 1 | Deletion of Nav1.7 leads to altered gene expression in DRG neurons. (a) The pie chart shows the number of signiﬁcantly differentially
expressed (DE) genes (analysis of variance P-valueo0.01) between Nav1.7 KO mice (n¼ 3) and wild-type littermates (n¼ 3), annotated with the top
enriched Gene Ontology (GO) terms regarding the Biological Process (BP). For the enrichments analysis, we used methods based both on gene counts,
namely the classical Fisher test, and gene ranks and scores, namely the Kolmogorov–Smirnov-type tests. (b) Example list of the fold change of differentially
expressed genes in sensory neurons from Nav1.7 KO mice. Complete data are available at GEO and ArrayExpress, accession code GSE61373.
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Figure 2 | Scn9a deletion increases Penk mRNA expression in DRG neurons. Reverse transcriptase–PCR (RT–PCR) analysis of Penk and Ceacam10 mRNA
expression in DRG relative to Gapdh mRNA levels in wild-type littermates and Nav1.7 KO mice. (a) Increased expression of Penk mRNA was observed in
both female Nav1.7 KOs (light pink column, n¼ 3) compared with female littermates (dark pink column, n¼ 3), as well as male Nav1.7 KOs (light blue
column, n¼ 3) compared with male littermates (dark blue column, n¼ 3). No difference was observed between wild-type females and wild-type males.
(b) Penk mRNA expression was not altered in Nav1.8 KOs compared with littermates (female Nav1.8 KOs: light pink column, n¼ 3; female littermates:
dark pink column, n¼ 3; male Nav1.8 KOs: light blue column, n¼ 3; male littermates: dark blue column, n¼ 3). (c) Ceacam10 mRNA was downregulated in
both female Nav1.7 KOs (light pink column, n¼ 3) compared with female littermates (dark pink column, n¼ 3) and male Nav1.7 KOs (light blue column,
n¼ 3) compared with male littermates (dark blue column, n¼ 3). (d) Downregulation of Ceacam10 mRNA was also observed in Nav1.8 KOs compared
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double-labelled with met-enkephalin (Green) and IB-4 (Red). Right panel insert shows higher magniﬁcation of lamina I and II within the dorsal horn.
(f) Quantiﬁcation of immunostaining signal shows less Met-enkephalin immunoreactivity in littermate dorsal horns (n¼ 3) compared with the Nav1.7 KO
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and ***Po0.001 (one-way analysis of variance with Bonferroni post test (a,b)). Immunoreactivity signal is expressed as mean±s.e.m. with signiﬁcance
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thresholds of littermate controls. Both female and male
Nav1.7-null mutants showed substantial reversal of analgesia
with naloxone (Fig. 4c,d).
We complemented the behavioural tests with electrophysiolo-
gical studies of nociceptive input into wide dynamic range (WDR)
neurons in the spinal cord of mice, adapting a published method30
(Fig. 4e,f). In these experiments, polysynaptic input from
peripheral neurons drives activity of deep dorsal horn neurons.
Action potentials elicited in second-order neurons of the dorsal
horn can then be used to quantify innocuous and noxious input
into the central nervous system. Such data are useful in that they
complement behavioural studies with numerical data on electrical
activity. Baseline evoked activity to mechanical and thermal
stimulation was lower in Nav1.7 KOs than in littermates and
naloxone enhanced WDR ﬁring in KO but not in littermate mice
in response to mechanical and thermal stimuli (Fig. 4e,f).
Innocuous input evoked by brush stimulation was little affected
(Fig. 4f). Both male and female null mutant Nav1.7 mice showed
enhanced dorsal horn ﬁring to noxious mechanical and thermal
input in the presence of naloxone, consistent with the behavioural
studies of naloxone action (Fig. 4e,f). Thus, opioid action in
Nav1.7-null mutant mice appears target nociceptive input from the
peripheral nervous system, consistent with expression of m-opioid
receptors on small nociceptive afferents, as well as the cellular
speciﬁcity of Nav1.7 deletion in the advillin-Cre Nav1.7 KO mice.
Ceacam10 was the most downregulated transcript in the Nav1.7
microarray analysis and thus we examined the effects of gene
deletion on pain behaviour as well. Ceacam10-null mutant mice
have a limited analgesic phenotype to thermal stimuli in the
Hargreaves test and the heterozygous null mutant mice also show
partial analgesia (Fig. 4g). Naloxone does not reverse the analgesic
phenotype of Ceacam10-null mice (Fig. 4g), suggesting that a
non-opioid-dependent mechanism may also make a small
contribution to the CIP analgesic phenotype associated with loss
of Nav1.7 expression.
Finally, we examined the effect of naloxone on pain thresholds
in a rare human Nav1.7-null CIP individual described and
genotyped in detail in ref. 31. Consistent with the KO mouse data,
there was a dramatic reversal of analgesia on infusion of
naloxone. The ability of the Nav1.7-null CIP individual to
detect a single noxious heat stimulus in the presence of naloxone
rose from 0 to 80% (Fig. 5a,b). In normal conditions, the Nav1.7-
null subject was completely unaware of the stimulus (Fig. 5a).
Ongoing thermal pain could also be detected by the Nav1.7-null
individual only in the presence of naloxone (Fig. 5c). As well as a
response to speciﬁc brief noxious stimuli, the CIP patient
mentioned general pain in one leg that had suffered several
fractures. It would be useful to examine larger numbers of the
extremely rare CIP individuals to extend these studies. None-
theless, the mechanistic studies in mice seem to also explain
aspects of the human Nav1.7-null CIP phenotype.
In summary, the loss of Nav1.7 expression in SCN9A-null mice
and humans leads to the upregulation of an endogenous opioid
system that contributes substantially to the CIP pain-free state
through inhibition of nociceptive sensory neuron input into the
spinal cord. The poor efﬁcacy of selective Nav1.7 blockers may be
explained in part by this genetic analysis. If a complete loss of
Nav1.7-mediated sodium ﬂux is required to upregulate the opioid
system, then even potent antagonists are likely to fail. We found
that TTX levels 410-fold higher than the IC50 for Nav1.7 were
required to partially recapitulate the upregulation of Penk mRNA
found in Nav1.7-null mutant sensory neurons, suggesting that a
complete block of sodium ﬂux through Nav1.7 is necessary for
Penk mRNA upregulation. Ongoing opioid-dependent analgesia
throughout the lifetime of the CIP individual is consistent with
recent studies on tonic opioid receptor activation in mice32. A
dramatic synergy in analgesia with co-administration of sodium
channel blockers and opioids has already been noted33.
Lowered levels of intracellular sodium have been causally linked
with increased Penk mRNA levels in the present mouse study,
consistent with a possible role for sodium as a second messenger.
Interestingly, clinical studies have reported increased levels of
circulating met-enkephalin associated with lowered systemic
sodium levels in idiopathic oedema34. The sodium and tonicity-
regulated transcription factor NFAT5 is present in both
nociceptive and non-nociceptive sensory neurons, and salt
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Figure 3 | Intracellular sodium concentration regulates Penk expression.
Time-course reverse transcriptase–PCR (RT–PCR) experiments were
performed to quantify expression of Penk and Ceacam10 mRNA in cultured
DRG neurons in response to intracellular changes in cation concentration
(n¼ 6 per group). (a) Monensin-mediated intracellular sodium rise
decreased Penk mRNA expression in DRG neurons. (b) Under the same
conditions, Ceacam10 mRNA level was upregulated. (c) Penk expression was
not altered by intracellular calcium rise induced by ionomycin, (d) whereas
Ceacam10mRNAwas signiﬁcantly upregulated after 1 h of incubation with the
calcium ionophore. (e) Exposure (6h) to the voltage-gated sodium channel
blocker TTX induces a dose-dependent upregulation of Penk expression.
(f) At the highest TTX concentration, 500nM, Ceacam10 expression level
was not altered. All RT–PCR data are expressed as mean±s.e.m. with
signiﬁcance indicated by *Po0.05, **Po0.01 and ***Po0.001 (one-way
analysis of variance with Dunnett’s post test or Student’s t-test).
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kinases such as SGK1 that regulate NFAT5 are also found in
sensory neurons28. Several copies of the NFAT5 consensus
sequence 50-TGGAAANYNY-30 are also found upstream of the
human PENK gene, so that the molecular apparatus deﬁned in the
kidney and heart for salt or tonicity regulation of gene expression
are also present in DRG sensory neurons22,23. This is a potential
mechanism for sodium regulation of opioid peptide expression.
The A-type G protein-coupled receptors that mediate the
actions of opioid peptides are also regulated by a sodium-binding
pocket that is linked to agonist binding and G protein coupled
receptor activity35. Thus, sodium downregulates both the
expression of opioid peptides and the activity of their cognate
receptors. A possible link between the electrical activity of the
voltage-gated sodium channel Nav1.7 and the expression and
activity of opioid peptides on their cognate receptors is suggested
by the present study. Sodium channels have been implicated in a
range of physiological functions other than action potential
propagation, including hormone secretion and tumour
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heterozygous KO mice show clear thermal analgesia in the Hargreaves test and this is unaffected by naloxone administration (n¼6 per genotype). Data
are expressed as mean±s.e.m. *Po0.05, **Po0.01 and ***Po0.001 signiﬁcance levels indicate differences between KOs and littermates using a Student’s
t-test and $Po0.05, $$Po0.01 and $$$ Po0.001 indicate differences following naloxone administration using a paired t-test.
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metastases4,36, although the molecular mechanisms underlying
these events are incompletely understood. It is possible that
sodium plays a regulatory role in some of these events. The
present observations provide a molecular rationale for the use of
selective Nav1.7 channel blockers that are likely to have few side
effects, in combination with presently available opioid drugs (or
enkephalinase inhibitors) for the treatment of a large number of
chronic pain conditions.
Methods
Animals. Both female and male mice aged 8–12 weeks were kept on a 12-h light/
dark cycle and provided with food and water ad libitum. Conditional Nav1.7 KO
mice were generated by crossing ﬂoxed (SCN9A) Nav1.7 mice with Advillin-Cre
mice7,16. Ceacam10 global null mutant mice on a BALBc background were
supplied by EMMA (EM:00196 BALB/c-Ceacam10). All experiments were
performed with approval from the United Kingdom Home Ofﬁce according to
guidelines set by personal and project licenses, as well as guidelines of the
Committee for Research and Ethical Issues of IASP.
Microarrays. Microarray data were obtained using the Affymetrix GeneChip
Mouse Genome 430 2.0 Array. Dorsal root ganglia from all spinal levels of lit-
termate control and Nav1.7-, Nav1.8- and Nav1.9-null mutants (n¼ 3) were
extracted with RNAeasy kits and triplicate replicates were analysed on the gene
arrays. Microarray data were deposited at Gene Expression Omnibus array express
for public use with reference number E-GEOD-61373.
DRG cultures. DRG from all spinal levels were harvested and dissociated using a
standard enzymatic protocol previously described18. Following incubation in Dispase
(Gibco)/collagenase (type XI, Sigma, UK) for 40min, DRGs were mechanically
triturated with three ﬁre-polished glass pipettes of decreasing diameters. DRG cells
were centrifuged and re-suspended in DMEM medium supplemented with 10% fetal
bovine serum, 1% Glutamax and 125 ngml 1 NGF (Sigma). Dissociated neurons
were plated on poly-L-lysine and Laminin-coated 35-mm plastic dishes (Nunc,
Denmark). Cultured DRG neurons were incubated with monensin (Sigma; in
ethanol absolute), TTX (Sigma; in extracellular solution) or ionomycin (Molecular
Probes, Life Technologies; in dimethyl sulfoxide) at concentrations described in the
ﬁgure legend before RNA extraction and quantiﬁcation. For each experiment, control
DRG neurons were treated with appropriate vehicle.
RNA quantiﬁcation. DRG from lumbar segments L4, L5 and L6 were dissected
and pooled. RNA was extracted using TRIzol Reagent (Invitrogen) according to the
manufacturer’s instructions. In the case of DRG cultures, DRG were ﬁrst dis-
sociated and incubated with the drugs for a given time before collection. Reverse
transcription was performed using iScript Reverse Transcription Supermix
for reverse transcriptase–qPCR following the supplied protocol by Bio-Rad.
Complementary DNA ampliﬁcation was performed in triplicate, using SsoAd-
vanced Universal SYBR Green Supermix (Bio-Rad). The following primers were
used (50–30): Gapdh forward TGCGACTTCAACAGCAACTC and reverse CTTG
CTCAGTGTCCTTGCTG; Penk forward TTCAGCAGATCGGAGGAGTTG and
reverse GAAGCGAACGGAGGAGAGAT; and Ceacam10 forward AGAATTAA
ATGCAAGGGGGC and reverse ATGAGGGAGCCTACGCACTA. DNA ampli-
ﬁcation was quantiﬁed with a Bio-Rad CFX Connect Real-Time PCR Detection
System thermocycler. The expression level of target genes was normalized to
housekeeping gene mRNA (Gapdh). Fold changes were determined using the
2DDCt equation in which wild-type littermate or vehicle-treated cultured DRG
cDNA samples were designated as the calibrator. The data presented are given as
the mean of the fold changes. Student’s t-test or one-way analysis of variance
followed by Dunnett’s post test were respectively used to compare expression levels
between two groups or three and more groups.
Immunohistochemistry. Mice were anaesthetized with intraperitoneal pento-
barbital and transcardially perfused with PBS (0.01% Heparin) and ice-cold paraf-
ormaldehyde (4% in PBS). Lumbar spinal cord fragments were dissected and post
ﬁxed for at least 1 h in paraformaldehyde and transferred to a sucrose solution
(0.3M) for cryoprotection. Tissues were embedded in optical coherence tomography
mounting medium, frozen in liquid nitrogen and stored at  80 C. Free-ﬂoating
sections (30mm) were blocked 1 h in PBS with 10% goat serum (Sigma) and 0.1%
Triton X-100, followed by overnight incubation at 4 C in Rabbit anti-met-enke-
phalin primary antibody (1:500 in PBS with 3% goat serum and 0.1% Triton X-100,
AB5026, Millipore). Co-staining with Isolectin B4 biotin conjugate (IB4, Sigma) was
used to label spinal cord lamina II. Corresponding monoclonal goat anti-rabbit met-
enkephalin (1:1,000 Alexa Fluor 488, A11017, Life Technology, UK) or anti-biotin
(1:1,000 Streptavidin Alexa Fluor 568 conjugate, S-11226, Life Technology) sec-
ondary antibodies were used. Spinal cord slices were imaged using a Leica TCS SP8
spectral confocal microscope (Leica Microsystems, Germany) using laser lines
488 nm (Met-enk) and 552 nm (IB4) at an acquisition frequency of 200Hz
(1,024 1,024 format). The laser power and acquisition frequency was kept constant
between all respective samples. The relative ﬂuorescence for met-enkephalin was
calculated by taking the mean ﬂuorescence of the entire dorsal horn (indicated by
IB4 staining) and subtracting background ﬂuorescence (LAS AF 3 analysis software).
The relative ﬂuorescence for each animal was taken as an average of at least three
spinal sections. Three animals were used per group.
Mouse behaviour. All behavioural experiments were performed by an experi-
menter blind to both genotype and treatment. Mechanical nociceptive thresholds
were measured using the Randall-Selitto test that applies pressure to the tail with a
3-mm2 blunt conical probe using a 500 g cutoff. Thermal nociceptive thresholds
were determined by measuring paw-withdrawal latency using the Hargreaves
apparatus at a ramp of 2.25 C s 1 with a 20-s cutoff. Naloxone hydrochloride
dihydrate (2mg kg 1 intraperitoneally, Sigma) was administered 30min before
behavioural assessment. Statistical differences between KOs and littermates,
as well as the effects of naloxone in each genotype group, were determined using a
two-way analysis of variance.
In vivo electrophysiology. Electrophysiological recordings were performed
by an experimenter blind to genotype. Mice were anaesthetized with isoﬂuorane
(4%; 66% N2O and 33% O2) and secured in a stereotaxic frame. Anaesthesia was
reduced and maintained at 1.5% isoﬂurane for the remaining duration of the
experiment. A laminectomy was performed to expose L3–L5 segments of the spinal
cord and extracellular recordings were made fromWDR neurons in the deep dorsal
horn (lamina III–V, 200–600 mm) using parylene-coated tungsten electrodes (A-M
Systems, USA) in Nav1.7 KO mice (n¼ 17 neurons) and littermate controls
(n¼ 24 neurons). Mechanical and thermal stimuli were applied to the peripheral
receptive ﬁeld of spinal neurons on the hindpaw glabrous skin and the evoked
activity of neurons was visualized on an oscilloscope and discriminated on a spike
amplitude and waveform basis using a CED 1401 interface coupled to Spike 2
software (Cambridge Electronic Design, UK). Natural stimuli (non-noxious 8 g von
Frey and noxious prod 100 g cm 2 mechanical stimulation; thermal water jet 40,
45 C) were applied in ascending order of intensity to receptive ﬁelds for 10 s and
the total number of evoked spikes recorded. Following baseline recordings of
evoked activity of deep dorsal horn neurons, naloxone was administered
(2mg kg 1 subcutaneously, Sigma) and evoked activity to natural stimuli was
characterized again. Statistical signiﬁcance for differences between littermates and
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Figure 5 | Naloxone dramatically reverses the analgesia associated with
Nav1.7-null mutations in a CIP individual. Perception of phasic pain.
The probability of detecting 9-ms radiant heat pulses was assessed in a
Nav1.7-null patient (a) and in three age-matched healthy controls (b).
Neodymium:yttrium-aluminum-perovskite (Nd:YAP) laser pulses (El.En,
Italy) selectively stimulate intra-epidermal free-nerve endings, thus
providing a pure nociceptive input without touch. The human Nav1.7 null did
not detect any stimuli in baseline and saline conditions. The probability of
detecting the stimulus dramatically increased to 80% of stimuli detected
during the infusion of 12mg naloxone, almost reaching the detection levels
of matched healthy controls. (c,d) Tonic pain was elicited by 25 s laser
stimuli, whereas the participants rated online the intensity of the heat
sensation on a visual analogue scale (0¼ no sensation, 100¼worst pain
imaginable) throughout the laser application. Again, naloxone strongly
enhanced tonic pain sensations in the Nav1.7-null patient (c) throughout the
time course of the stimulation without effect in the control subjects (d).
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KOs was determined using a t-test; effects of naloxone on littermates and KOs were
determined using paired t-tests.
Human behaviour. All participants gave written informed consent. The study was
approved by the UCL Research Ethics Committee. The CIP patient was a 39-year-
old woman. Healthy controls were age matched (N¼ 3, mean age±s.d.: 38.7±3.2).
Perception of phasic and tonic radiant heat was assessed at baseline and during
intravenous administration of saline or naloxone (12mg), in a randomized order.
Psychophysical assessment was carried out by an experimenter blind to the
pharmacological condition. Radiant heat was generated by an infrared neody-
mium:yttrium-aluminum-perovskite laser with a wavelength of 1.34 mm (Electro-
nical Engineering, Italy). This method was used to selectively activate free nerve
endings in the superﬁcial layers of the hairy skin37,38. The laser ﬂuency was
0.6 Jmm 2 and the duration of each laser pulse was 9ms. After each of the ten
pulses delivered at random intervals (15–40 s) to the forearm, participants were
asked to verbally report whether they detected any stimulus. Tonic radiant heat was
generated by a CO2 laser, whose power is regulated using a feedback control based
on an online measurement of skin temperature at the site of stimulation (Laser
Stimulation Device, SIFEC, Belgium). On each trial, tonic radiant heat was
delivered to the forearm for 25 s, at one of three possible temperatures: 42, 45 and
48 C (ref. 37). Participants were asked to rate the intensity of the thermal sensation
on a visual analogue scale throughout the trial (0¼ no sensation, 100¼worst pain
imaginable). Three trials per stimulus temperature were given on each session
(baseline, saline and naloxone) in a randomized order.
References
1. Breivik, H., Collett, B., Ventafridda, V., Cohen, R. & Gallacher, D. Survey of
chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur. J.
Pain 10, 287–333 (2006).
2. Eijkelkamp, N. et al. Neurological perspectives on voltage-gated sodium
channels. Brain 135, 2585–2612 (2012).
3. Waxman, S. G. et al. Sodium channel genes in pain-related disorders:
phenotype-genotype associations and recommendations for clinical use. Lancet
Neurol. 13, 1152–1160 (2014).
4. Zhang, Q. et al. Naþ current properties in islet alpha- and beta-cells reﬂect
cell-speciﬁc Scn3a and Scn9a expression. J. Physiol. 592, 4677–4696 (2014).
5. Weiss, J. et al. Loss-of-function mutations in sodium channel Nav1.7 cause
anosmia. Nature 472, 186–190 (2011).
6. Cox, J. J. et al. An SCN9A channelopathy causes congenital inability to
experience pain. Nature 444, 894–898 (2006).
7. Minett, M. S. et al. Distinct Nav1.7-dependent pain sensations require different
sets of sensory and sympathetic neurons. Nat. Commun. 3, 791 (2012).
8. Gingras, J. et al. Global Nav1.7 knockout mice recapitulate the phenotype of
human congenital indifference to pain. PLoS ONE 9, e105895 (2014).
9. Estacion, M. et al. Ca2þ toxicity due to reverse Naþ /Ca2þ exchange
contributes to degeneration of neurites of DRG neurons induced by a
neuropathy-associated Nav1.7 mutation. J. Neurophysiol. 114, 1554–1564 (2015).
10. Minett, M. S. et al. Pain without nociceptors? Nav1.7-independent pain
mechanisms. Cell Rep. 6, 301–312 (2014).
11. Raouf, R. et al. Sodium channels and mammalian sensory
mechanotransduction. Mol. Pain 8, 21 (2012).
12. Schmalhofer, W. A. et al. ProTx-II, a selective inhibitor of NaV1.7 sodium
channels, blocks action potential propagation in nociceptors. Mol. Pharmacol.
74, 1476–1484 (2008).
13. Lee, J. H. et al. A monoclonal antibody that targets a Nav1.7 channel voltage
sensor for pain and itch relief. Cell 157, 1393–1404 (2014).
14. Lotze, M. T. & Tracey, K. J. High-mobility group box 1 protein (HMGB1):
nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 5, 331–342 (2005).
15. Ronjat, M., Kiyonaka, S., Barbado, M., De Waard, M. & Mori, Y. Nuclear life of
the voltage-gated Cacnb4 subunit and its role in gene transcription regulation.
Channels (Austin) 7, 119–125 (2013).
16. Nassar, M. A. et al. Nociceptor-speciﬁc gene deletion reveals a major role for
Nav1.7 (PN1) in acute and inﬂammatory pain. Proc. Natl Acad. Sci. USA 101,
12706–12711 (2004).
17. Akopian, A. N. et al. The tetrodotoxin-resistant sodium channel SNS has a
specialized function in pain pathways. Nat. Neurosci. 2, 541–548 (1999).
18. Baker, M. D., Chandra, S. Y., Ding, Y., Waxman, S. G. & Wood, J. N. GTP-
induced tetrodotoxin-resistant Naþ current regulates excitability in mouse
and rat small diameter sensory neurones. J. Physiol. 548, 373–382 (2003).
19. Bodnar, R. J. Endogenous opiates and behavior: 2013. Peptides 62, 67–136 (2014).
20. Finkenzeller, D. et al. Carcinoembryonic antigen-related cell adhesion molecule
10 expressed speciﬁcally early in pregnancy in the decidua is dispensable for
normal murine development. Mol. Cell Biol. 23, 272–279 (2003).
21. Kuroda, H. et al. Sodium-calcium exchangers in rat trigeminal ganglion
neurons. Mol. Pain 9, 22 (2013).
22. Popov, S. et al. Increases in intracellular sodium activate transcription and gene
expression via the salt-inducible kinase 1 network in an atrial myocyte cell line.
Am. J. Physiol. Heart Circ. Physiol. 303, H57–H65 (2012).
23. Miyakawa, H., Woo, S. K., Dahl, S. C., Handler, J. S. & Kwon, H. M.
Tonicity-responsive enhancer binding protein, a rel-like protein that stimulates
transcription in response to hypertonicity. Proc. Natl Acad. Sci. USA 96,
2538–2542 (1999).
24. Brown, D. A. & Scholﬁeld, C. N. Changes of intracellular sodium and
potassium ion concentrations in isolated rat superior cervical ganglia induced
by depolarizing agents. J. Physiol. 242, 307–319 (1974).
25. Gorczynska, E. & Handelsman, D. J. Requirement for transmembrane sodium
ﬂux in maintenance of cytosolic calcium levels in rat Sertoli cells. Am. J. Physiol.
264, E863–E867 (1993).
26. Sivilotti, L., Okuse, K., Akopian, A. N., Moss, S. & Wood, J. N. A single serine
residue confers tetrodotoxin insensitivity on the rat sensory-neuron-speciﬁc
sodium channel SNS. FEBS Lett. 409, 49–52 (1997).
27. Sawynok, J., Pinsky, C. & LaBella, F. S. On the speciﬁcity of naloxone as an
opiate antagonist. Life Sci. 25, 1621–1632 (1979).
28. Usoskin, D. et al. Unbiased classiﬁcation of sensory neuron types by large-scale
single-cell RNA sequencing. Nat. Neurosci. 18, 145–153 (2015).
29. Minett, M. S., Quick, K. & Wood, J. N. in Current Protocols in Mouse Biology
(John Wiley & Sons, Inc., 2011).
30. Urch, C. E. & Dickenson, A. H. In vivo single unit extracellular recordings
from spinal cord neurones of rats. Brain Res. Brain Res. Protoc. 12, 26–34
(2003).
31. Nilsen, K. B. et al. Two novel SCN9A mutations causing insensitivity to pain.
Pain 143, 155–158 (2009).
32. Corder, G. et al. Constitutive mu-opioid receptor activity leads to long-term
endogenous analgesia and dependence. Science 341, 1394–1399 (2013).
33. Kolesnikov, Y. A., Chereshnev, I. & Pasternak, G. W. Analgesic synergy
between topical lidocaine and topical opioids. J. Pharmacol. Exp. Ther. 295,
546–551 (2000).
34. Bhathena, S. J. et al. Opioid peptides, adrenocorticotrophic hormone, and
idiopathic (orthostatic) edema. Am. J. Med. Sci. 308, 133–137 (1994).
35. Katritch, V. et al. Allosteric sodium in class A GPCR signaling. Trends Biochem.
Sci. 39, 233–244 (2014).
36. Patel, F. & Brackenbury, W. J. Dual roles of voltage-gated sodium channels in
development and cancer. Int. J. Dev. Biol. (2015).
37. Churyukanov, M., Plaghki, L., Legrain, V. & Mouraux, A. Thermal detection
thresholds of Adelta- and C-ﬁbre afferents activated by brief CO2 laser pulses
applied onto the human hairy skin. PLoS ONE 7, e35817 (2012).
38. Iannetti, G. D., Zambreanu, L. & Tracey, I. Similar nociceptive afferents
mediate psychophysical and electrophysiological responses to heat stimulation
of glabrous and hairy skin in humans. J. Physiol. 577, 235–248 (2006).
Acknowledgements
We thank the MRC, ARUK, BK21 programme at SNU and the Wellcome Trust for their
generous support.
Author contributions
M.S.M., V.P., J.Z., J.J.C. and J.N.W. designed the study. S.S. carried out electro-
physiological studies. V.P., A.M. and A.H.K. carried out cell and molecular experiments.
F.M., G.D. and R.M. carried out the human studies. G.B. carried out bioinformatics
analysis. M.S.M., Y.D.B., S.L., S.S.V. and Q.M. provided and analysed transgenic mice in
behavioural assays. J.N.W. wrote the paper, to which all authors contributed.
Additional information
Accession codes: Microarray data of DRG tissues extracted from Nav1.7 KO, Nav1.8 KO
and Nav1.9 KO mice are available in the ArrayExpress and Gene Expression Omnibus
(GEO) databases, accession code GSE61373.
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing ﬁnancial interests: The authors declare no competing ﬁnancial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Minett, M. S. et al. Endogenous opioids contribute to
insensitivity to pain in humans and mice lacking sodium channel Nav1.7. Nat. Commun.
6:8967 doi: 10.1038/ncomms9967 (2015).
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise
in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material.
To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9967
8 NATURE COMMUNICATIONS | 6:8967 |DOI: 10.1038/ncomms9967 | www.nature.com/naturecommunications
